甲状旁腺功能减退症 中国就医指南

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands, leading to chronic hypocalcemia, hyperphosphatemia, and impaired mineral metabolism. PTH is essential for maintaining calcium homeostasis through its actions on bone, kidneys, and the gastrointestinal tract—stimulating bone resorption, renal calcium reabsorption, and activation of vitamin D. The most common cause is accidental damage or removal of the parathyroid glands during thyroid or parathyroid surgery (post-surgical hypoparathyroidism), accounting for over 75% of cases. Other etiologies include autoimmune polyglandular syndrome type 1 (APS-1), genetic disorders (e.g., mutations in the CASR, GCM2, or AIRE genes), infiltrative diseases (e.g., hemochromatosis, Wilson disease), radiation-induced gland dysfunction, and idiopathic forms. Epidemiologically, hypoparathyroidism affects approximately 30–50 per million people globally, with an estimated prevalence of 0.003–0.005% in the general population. Incidence rises significantly among patients undergoing total thyroidectomy—ranging from 0.5% to 5% for transient cases and 0.2% to 2% for permanent disease. Risk factors include female sex, autoimmune thyroid disease (e.g., Hashimoto’s thyroiditis), prior neck surgery or radiotherapy, genetic predisposition (especially in familial isolated hypoparathyroidism or APS-1), and certain syndromic conditions like DiGeorge syndrome. Untreated or poorly managed hypoparathyroidism leads to debilitating neuromuscular symptoms—including paresthesias, muscle cramps, carpopedal spasm, laryngospasm, seizures, and cardiac arrhythmias—and long-term complications such as basal ganglia calcification, cataracts, dental enamel hypoplasia, and cognitive impairment. Quality of life is substantially compromised: patients frequently report chronic fatigue, anxiety, depression, brain fog, sleep disturbances, and reduced physical functioning. Even with treatment, many experience persistent symptoms due to narrow therapeutic windows, fluctuating calcium levels, and challenges in achieving stable mineral balance. Lifelong monitoring and individualized therapy are critical—not only to prevent acute crises but also to mitigate cumulative organ damage and preserve neurocognitive health. Patient education, dietary counseling (calcium-rich foods, low-phosphate diet), and regular surveillance of serum calcium, phosphate, magnesium, creatinine, and urinary calcium are integral components of care. As awareness grows and newer therapies (e.g., recombinant human PTH 1–84) become more accessible in specialized centers, multidisciplinary management involving endocrinologists, nephrologists, and nutrition specialists is increasingly emphasized.

# 甲状旁腺功能减退症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：术后性、特发性或轻中度低钙血症患者（血钙≥1.8 mmol/L，无癫痫/喉痉挛急性发作）

• •基础药物治疗：

- 血钙、磷、PTH、25(OH)D、尿钙等每3个月复查：380–520元/次

• •高阶个体化方案（需动态钙监测及剂量滴定）：含24h尿钙、心电图、肾超声评估，年均总费用 8,000–15,000元

二、手术/介入治疗方案

注：本病极少需手术；仅适用于继发于颈部重复手术致甲状旁腺自体移植失败、或罕见异位甲状旁腺瘤导致的“假性甲旁减”鉴别困难者。

• •术前精准定位检查（99mTc-MIBI双时相显像+颈部增强MRI）：2,600–3,800元
• •微创探查/自体移植术（需术中PTH快速检测）：住院全周期费用 32,000–48,000元（含麻醉、手术、监护、病理）

三、特殊复杂情况处理

• •难治性低钙血症（反复抽搐、基底节钙化）：启用重组人PTH（特立帕肽）皮下注射，月均药费 12,000–18,000元
• •慢性肾病合并甲旁减：需联合司维拉姆降磷+限磷饮食管理，年均综合管理费 20,000–35,000元

四、方案快速选择指南

• •预算≤1万元/年：优选标准钙+骨化三醇方案（基层医院随访）
• •预算1–3万元/年+频繁发作：升级至动态监测+个体化剂量调整（三甲内分泌科专病门诊）
• •确诊为移植失败或肿瘤性病因：转诊至具备术中PTH检测能力的三甲医院行精准外科干预